A phase II randomized placebo-controlled study of fisetin to improve physical function in breast cancer survivors: the TROFFi study rationale and trial design
Jingran Ji(Northwestern University), Mina S. Sedrak(University of California, Los Angeles), Laura Petersen(APLA Health), Lisa D. Yee(City of Hope), Catherine Lee(University of California, Los Angeles), Yuliya Zekster(University of California, Los Angeles), George A. Kuchel(UConn Health), James Kirkland(Cedars-Sinai Medical Center), Ali Al-Saleem(University of California, Los Angeles), Claire S. Smith(University of California, Los Angeles), H. J. Cohen(Duke University), Tamar Tchkonia(Cedars-Sinai Medical Center), Tamara S. Evans(Cedars-Sinai Medical Center), Nala Son(University of California, Los Angeles), Catherine M. Crespi(University of California, Los Angeles)
Cited by 1
Related Papers
Breast Cancer in Younger Women: Reproductive and Late Health Effects of Treatment
|Journal of Clinical Oncology|2003|530
Breast cancer survivors: Psychosocial concerns and quality of life
|Breast Cancer Research and Treatment|1996|496
Geriatric Assessment–Driven Intervention (GAIN) on Chemotherapy-Related Toxic Effects in Older Adults With Cancer
|JAMA Oncology|2021|464
Neurocognitive Performance in Breast Cancer Survivors Exposed to Adjuvant Chemotherapy and Tamoxifen
|Journal of Clinical and Experimental Neuropsychology|2004|400
Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10 years after chemotherapy
|Breast Cancer Research and Treatment|2006|399